nanostring technologies (nasdaq: nstg) is a publicly held provider of life science tools for translational research and molecular diagnostics. the company's technology enables a wide variety of basic research, translational medicine and in vitro diagnostics applications. nanostring technologies provides life science tools for translational research and molecular diagnostic products. the company's ncounter® analysis system, which has been employed in basic and translational research since it was first introduced in 2008 and cited in more than 300 peer-reviewed publications, has also now been applied to diagnostic use as the ncounter dx analysis system. the company's technology offers a cost-effective way to easily profile the expression of hundreds of genes, mirnas, or copy number variations, simultaneously with high sensitivity and precision. the company's technology enables a wide variety of basic research and translational medicine applications, including biomarker discovery and vali
Company profile
Ticker
NSTG
Exchange
Website
CEO
R. Bradley Gray
Employees
Incorporated
Location
Fiscal year end
Industry (SIC)
SEC CIK
Corporate docs
Subsidiaries
NanoString Technologies Europe Limited • NanoString Technologies SAS • NanoString Technologies International, Inc. • NanoString Technologies Germany GmbH • NanoString Technologies Asia Pacific Limited • NanoString Technologies Singapore Pte Limited • NanoString Technologies (Beijing) Co. Ltd. • NanoString Technologies Spain, S.L. • NanoString Technologies Netherlands B.V. ...
IRS number
200094687
NSTG stock data
Latest filings (excl ownership)
8-K
Material Modifications to Rights of Security Holders
28 May 24
8-K
Regulation FD Disclosure
22 May 24
NT 10-Q
Notice of late quarterly filing
10 May 24
8-K
Material Modifications to Rights of Security Holders
8 May 24
8-K
Bruker Completes Asset Acquisition of NanoString Business
6 May 24
8-K
Regulation FD Disclosure
22 Apr 24
8-K
NanoString Technologies to Be Acquired by Bruker Corporation
19 Apr 24
25-NSE
Exchange delisting
9 Apr 24
8-K
Regulation FD Disclosure
22 Mar 24
NT 10-K
Notice of late annual filing
15 Mar 24
Transcripts
NSTG
Earnings call transcript
2023 Q3
6 Nov 23
NSTG
Earnings call transcript
2023 Q2
3 Aug 23
NSTG
Earnings call transcript
2023 Q1
3 May 23
NSTG
Earnings call transcript
2022 Q4
28 Feb 23
NSTG
Earnings call transcript
2022 Q3
7 Nov 22
NSTG
Earnings call transcript
2022 Q2
7 Aug 22
NSTG
Earnings call transcript
2022 Q1
11 May 22
NSTG
Earnings call transcript
2021 Q4
2 Mar 22
NSTG
Earnings call transcript
2021 Q3
10 Nov 21
NSTG
Earnings call transcript
2021 Q2
5 Aug 21
Latest ownership filings
Financial summary
Quarter (USD) | Sep 23 | Jun 23 | Mar 23 | Dec 22 | |
---|---|---|---|---|---|
Revenue | |||||
Cost of revenue | |||||
Operating income | |||||
Operating margin | |||||
Net income | |||||
Net profit margin | |||||
Cash on hand | |||||
Change in cash | |||||
Diluted EPS |
Annual (USD) | Dec 22 | Dec 21 | Dec 20 | Dec 19 | |
---|---|---|---|---|---|
Revenue | |||||
Cost of revenue | |||||
Operating income | |||||
Operating margin | |||||
Net income | |||||
Net profit margin | |||||
Cash on hand | |||||
Change in cash | |||||
Diluted EPS |
Cash burn rate (est.) | Burn method: Change in cash | Burn method: Operating income | Burn method: FCF (opex + capex) | Last Q | Avg 4Q | Last Q | Avg 4Q | Last Q | Avg 4Q |
---|---|---|---|---|---|---|
Cash on hand (at last report) | 94.10 mm | 94.10 mm | 94.10 mm | 94.10 mm | 94.10 mm | 94.10 mm |
Cash burn (monthly) | 6.94 mm | 1.91 mm | 12.49 mm | 13.85 mm | 6.57 mm | 9.58 mm |
Cash used (since last report) | 57.96 mm | 15.98 mm | 104.22 mm | 115.60 mm | 54.80 mm | 79.97 mm |
Cash remaining | 36.14 mm | 78.12 mm | -10.12 mm | -21.50 mm | 39.29 mm | 14.13 mm |
Runway (months of cash) | 5.2 | 40.8 | -0.8 | -1.6 | 6.0 | 1.5 |
Institutional ownership, Q1 2024
13.2% owned by funds/institutions
13F holders | Current |
---|---|
Total holders | 3 |
Opened positions | 0 |
Closed positions | 8 |
Increased positions | 0 |
Reduced positions | 1 |
13F shares | Current |
---|---|
Total value | 54.14 mm |
Total shares | 6.35 mm |
Total puts | 0.00 |
Total calls | 0.00 |
Total put/call ratio | – |
Largest owners | Shares | Value |
---|---|---|
Clarus Lifesciences II | 4.12 mm | $50.33 mm |
Titanite Investment Management | 1.80 mm | $792.00 k |
Alger Associates | 432.68 k | $3.02 mm |
Recent insider trades
Date | Owner | Security | Transaction | Code | Indirect | 10b5-1 | $Price | #Shares | $Value | #Remaining |
---|---|---|---|---|---|---|---|---|---|---|
6 May 24 | Finney Elisha W | Common Stock | Option exercise | Acquire M | No | No | 0 | 41,133 | 0.00 | 62,579 |
6 May 24 | Finney Elisha W | RSU Common Stock | Option exercise | Dispose M | No | No | 0 | 41,133 | 0.00 | 0 |
6 May 24 | Norden Gregory | Common Stock | Option exercise | Acquire M | No | No | 0 | 41,133 | 0.00 | 88,552 |
6 May 24 | Norden Gregory | RSU Common Stock | Option exercise | Dispose M | No | No | 0 | 41,133 | 0.00 | 0 |
6 May 24 | Jonathan Todd Garland | Common Stock | Option exercise | Acquire M | No | No | 0 | 200,000 | 0.00 | 200,000 |
6 May 24 | Jonathan Todd Garland | RSU Common Stock | Option exercise | Dispose M | No | No | 0 | 200,000 | 0.00 | 0 |
6 May 24 | Waite Charles P JR | Common Stock | Option exercise | Acquire M | No | No | 0 | 41,133 | 0.00 | 79,284 |
6 May 24 | Waite Charles P JR | RSU Common Stock | Option exercise | Dispose M | No | No | 0 | 41,133 | 0.00 | 0 |
6 May 24 | R Bradley Gray | Common Stock | Option exercise | Acquire M | No | No | 0 | 354,545 | 0.00 | 1,108,477 |
6 May 24 | R Bradley Gray | Common Stock | Option exercise | Acquire M | No | No | 0 | 236,364 | 0.00 | 753,932 |